@entity3352 , @entity6478 , or @entity14292 for Treating Hypokalemia in XXXX .

@entity1 @entity1369 @entity470 @entity14292 @entity6478 @entity1372 @entity4861 @entity972 @entity916 @entity3352 @entity551 @entity1760
@entity1 with @entity4861 ( @entity4861 ), an inherited salt-losing tubulopathy, are usually treated with @entity972 -sparing diuretics or nonsteroidal anti-inflammatory drugs and oral @entity972 and @entity1760 supplementations. However, evidence supporting these treatment options is limited to case series studies. We designed an open-label, randomized, crossover study with blind end point evaluation to compare the efficacy and safety of 6-week treatments with one time daily 75 mg slow-release @entity3352 , 150 mg @entity14292 , or 20 mg @entity6478 added to constant @entity972 and @entity1760 supplementation in 30 @entity1 with @entity4861 (individual participation: 48 weeks). Baseline plasma @entity972 concentration was 2.8  0.4 mmol/L and increased by 0.38 mmol/L (95% confidence interval [95% CI], 0.23 to 0.53; P<0.001) with @entity3352 , 0.15 mmol/L (95% CI, 0.02 to 0.29; P=0.03) with @entity14292 , and 0.19 mmol/L (95% CI, 0.05 to 0.33; P<0.01) with @entity6478 . Fifteen @entity1 became normokalemic: six with @entity3352 , three with @entity14292 , and six with @entity6478 . @entity3352 significantly reduced @entity470 and plasma @entity916 concentration. @entity14292 and @entity6478 each increased plasma @entity1369 by 3-fold and @entity916 concentration slightly but did not significantly change @entity470 . BP did not significantly change. Eight @entity1 discontinued treatment early because of gastrointestinal intolerance to @entity3352 (six @entity1 ) and @entity551 with @entity14292 (two @entity1 ). In conclusion, each drug increases plasma @entity972 concentration in @entity1 with @entity4861 . @entity3352 was the most effective but can cause gastrointestinal intolerance and decreased @entity470 . @entity6478 and @entity14292 have similar but lower efficacies and increase @entity1372 depletion. The benefit/risk ratio of each drug should be carefully evaluated for each @entity1 .
